GU Oncology Clinical Trials

Untreated Localized Prostatic Adenocarcinoma

RTOG-0924

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Learn more.


Untreated Localized Prostatic Adenocarcinoma

NRG-GU005

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Learn more.


Localized Prostatic Adenocarcinoma (Post-prostatectomy)

NRG-GU002

Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Learn more.


Recurrent prostatic adenocarcinoma

NRG-GU006

A Phase II, Double-blinded, Placebo-controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide In Recurrent Prostate Cancer

Learn more.


Metastatic prostatic adenocarcinoma (Castration-resistant)

EA8153

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel

Learn more.


Muscle Invasive and Locally Advanced Urothelial Carcinoma

A031501

Phase III Randomized Adjuvant study of MK3475 (Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma versus Observation

Learn more.


Localized RCC (resectable)

EA8143

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Learn more.


PSMA-positive Metastatic Castration Resistant Prostate Cancer

Endocyte

PSMA-617-01

An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer

Learn more.

Need assistance?

Contact us